Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Table 2

Rate of adjuvant trastuzumab therapy in HER2-positive patients.

Year of diagnosis	Total number of HER2-positive patients (𝑁)	Trastuzumab received
		Total	Premenopausal	Postmenopausal
2000	21	0/21 (0%)	0/10 (0%)	0/11 (0%)
2001	83	1/83 (1%)	0/19 (0%)	1/64 (2%)
2002	79	2/79 (3%)	2/22 (9%)	0/57 (0%)
2003	99	2/99 (2%)	1/28 (4%)	1/71 (1%)
2004	95	2/95 (2%)	0/26 (0%)	2/69 (3%)
2005	97	34/97 (35%)	11/23 (48%)	23/74 (31%)
2006	110	42/110 (38%)	18/31 (58%)	24/79 (30%)
2007	97	57/97 (59%)	15/19 (79%)	42/78 (54%)
2008	90	53/90 (59%)	15/19 (79%)	38/71 (54%)
2009	117	64/117 (55%)	21/33 (64%)	43/84 (51%)
2010	114	65/114 (57%)	19/29 (66%)	46/85 (54%)
2011	65	43/65 (66%)	20/22 (91%)	23/43 (54%)
2012	67	24/67 (36%)	11/24 (46%)	13/43 (30%)
Total	1134	389/1134 (34%)	133/305 (44%)	256/829 (31%)